An angioplasty is a procedure performed to improve blood flow in the body’s arteries and veins. In an angioplasty procedure, imaging techniques are used to guide a balloon tipped catheter (a very thin tube) into an artery or a vein and advance it to where the vessel is blocked or narrowed. The balloon is then<a href="https://solaci.org/en/2015/06/01/n-2528/" title="Read more" >...</a>
Duration of double antiaggregation therapy in patients with oral anticoagulation
Original title: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent ImplantationThe ISAR-TRIPLE Trial. Reference: Katrin A. Fiedler et al. J Am Coll Cardiol. 2015;65(16):1619-1629. Patients with oral anticoagulation indication after drug eluting stenting require aspirin and clopidogrel; however, the triple scheme has high bleeding risk and optimal duration is yet to be determined. The<a href="https://solaci.org/en/2015/04/20/n-5139/" title="Read more" >...</a>
Long term ticagrelor after an acute myocardial infarction
Original title: Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. PEGASUS-TIMI 54. Referencia: Marc P. Bonaca et al. N Engl J Med. 2015 Mar 14. Patients with acute myocardial infarction (AMI) have an increased risk of recurrent events suggesting that this population could benefit from intensive secondary prevention. Current guidelines recommend adding to aspirin an<a href="https://solaci.org/en/2015/04/16/n-5132/" title="Read more" >...</a>
Double Anti platelet aggregation would be sufficient for six months after angioplasty in patients with stable coronary disease NSTSEACS.
Original title: 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug. Reference: Eluting Stents in Patients Nonresistant to Aspirin The Randomized, Multicenter ITALIC Trial. JACC.VOL. 65, NO. 8, 2015 Current recommendations on dual antiplatelet therapy (DAPT) are under review, particularly in acute coronary events due largely to the advent of second-generation stents. This work studied the hypothesis<a href="https://solaci.org/en/2015/03/10/n-5041/" title="Read more" >...</a>
Risks and benefits of Dual Antiplatelet beyond the year of a drug-eluting stent
Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. Reference: Laura Mauri et al. N Engl J Med 2014;371:2155-66. Dual antiplatelet therapy is recommended after a drug-eluting stent to prevent thrombotic complications. The clinical benefit of this scheme it is not clear beyond one year. Patients were registered to receive a<a href="https://solaci.org/en/2015/01/13/n-4901/" title="Read more" >...</a>
Less Definite Thrombosis with Everolimus Eluting Stents
Original title: Three-Year Outcomes After Revascularization With Everolimus-and Sirulimus -Eluting Stents From the SORT OUT IV Trial. Reference: Lisette Okkels Jensen et al. J Am CollCardiolIntv, 2014;7: 840-8. Drug eluting stents (DES) have been shown to safely and effectively reduce restenosis compared to bare-metal stents. While the risk of thrombosis remains a matter of concern when it comes<a href="https://solaci.org/en/2014/08/29/n-4712/" title="Read more" >...</a>
Hemodialysis Associated to Higher Incidence of In Stent Thrombosis
Original title: Impact of hemodialysis on local vessel healing and thrombus formation after drug-eluting stent implantation. Reference: Akihide Konishi, et al. Journal of Cardiology 2014;64:25-31 Even though the benefit of DES implantation to the general population is undeniable, it has been proved lower in hemodialysis patients (HD); the reason behind this phenomenon remains unclear. 121 patients received<a href="https://solaci.org/en/2014/08/08/n-4656/" title="Read more" >...</a>
Proximal protection devices could be the first choice for most carotid artery stenting procedures
Original title: Evaluation of proximal protection devices during carotid artery stenting as the first choice for embolic protection. Reference: Hornung M et al. EuroIntervention. 2014; Epub ahead of print. This series of the Frankfurt CardioVascular Center included 124 consecutive patients undergoing carotid angioplasty with proximal protection. The first 92 patients received the Gore Flow Reversal System (WL Gore;<a href="https://solaci.org/en/2014/07/31/n-4635/" title="Read more" >...</a>
Thrombosis with bioresorbable scaffolds: the story of DES all over again?
Original title: Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. Reference: Capodanno D et al. EuroIntervention. 2014 Jul 18. Epub ahead of print The GHOST-EU registry, that included 1189 patients from 10 European centers between 2011 and 2014, is now the largest registry<a href="https://solaci.org/en/2014/07/30/n-4628/" title="Read more" >...</a>
3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.
Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug eluting stents. Reference: El-Hayek G et al. Am J Cardiol. 2014; Epub ahead of print. This meta-analysis examined the data of four randomized and controlled studies (EXCELLENT, PRODIGY, RESET y OPTIMIZE) including 8157 patients receiving sirolimus, paclitaxel, everolimus or zotarolimus<a href="https://solaci.org/en/2014/06/24/n-4551/" title="Read more" >...</a>